Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER). This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I.
The effect of FGFR4 Gly388Arg polymorphism on treatment outcomes after chemoradiotherapy in esophageal cancer patients. This is an ASCO Meeting Abstract from the 2014 ASCO Annual Meeting I. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results